Unitat d'Epidemiologia i Registre de Càncer de Girona (UERCG), Pla Director d'Oncologia, Departament de Salut, Institut d'Investigació Biomèdica de Girona (IdIBGi), C/ Carrer del Sol, 15, ES-17004 Girona, Spain.
Clin Transl Oncol. 2012 Jun;14(6):458-64. doi: 10.1007/s12094-012-0824-0.
The aim of this study is to analyse the evolution of the survival of patients diagnosed with prostate cancer during the period 1995-2003.
This is a population survival study of incident cases of prostate cancer in four Spanish areas: Basque Country, Girona, Murcia and Navarra. We calculated the relative survival (RS) at 5 years and its 95% confidence intervals using a cohort analysis and adjusted for age. To assess the trend in survival between the periods (1995-1999 and 2000-2003) a Poisson regression model was used, adjusting for age, region and period, obtaining the relative risk of death.
The number of patients diagnosed during the 1995- 1999 period was 6493 and 8331 in the period 2000-03. The RS at 5 years adjusted for age increased significantly, from 75.3% (95% CI 73.3-77.2) in the period 1995-99 to 85% (95% CI 83.4-86.4) in the period 2000-03.
In Spain the survival of patients with prostate cancer has increased significantly from 1999 to 2003, probably due to the advancement in diagnosis produced by the opportunistic screening of prostate-specific antigen (PSA). Differences in the dissemination and use of the PSA level could explain the observed geographic differences in the increase of survival. It would be necessary to carry out studies to quantify the produced overdiagnosis by screening with PSA in prostate cancer.
本研究旨在分析 1995-2003 年间前列腺癌患者的生存演变情况。
这是对四个西班牙地区(巴斯克地区、赫罗纳、穆尔西亚和纳瓦拉)的前列腺癌新发病例进行的人群生存研究。我们使用队列分析计算了 5 年相对生存率(RS)及其 95%置信区间,并按年龄进行了调整。为了评估生存趋势在两个时期(1995-1999 年和 2000-2003 年)之间,我们使用泊松回归模型进行了调整,包括年龄、地区和时期,得出死亡的相对风险。
1995-1999 年期间诊断的患者人数为 6493 人,2000-03 年期间为 8331 人。经年龄调整后的 5 年 RS 显著提高,从 1995-99 年期间的 75.3%(95%CI 73.3-77.2)提高到 2000-03 年期间的 85%(95%CI 83.4-86.4)。
在西班牙,前列腺癌患者的生存率从 1999 年到 2003 年显著提高,这可能是由于前列腺特异性抗原(PSA)的机会性筛查提高了诊断水平。PSA 水平的传播和使用差异可能解释了观察到的生存提高的地理差异。有必要开展研究来量化 PSA 筛查在前列腺癌中的过度诊断。